Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission

Efavirenz-based first-line regimens have been widely used for children ≥3 years of age starting antiretroviral therapy, despite possible resistance with prior exposure to non-nucleoside reverse transcriptase inhibitors for prevention of mother-to-child transmission (PMTCT). We used logistic regression to examine the association between PMTCT exposure and viral failure (VF) defined as two consecutive viral loads (VL)>1000 copies/ml between 6–18 months on ART. Children with previous nevirapine exposure for PMTCT were not at higher risk of VF compared to unexposed children (adjusted Odds Ratio (aOR): 0.79; 95% CI:0.56, 1.11).

[1]  A. Turkova,et al.  Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV , 2019, Therapeutic drug monitoring.

[2]  R. Shapiro,et al.  Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. , 2018, The New England journal of medicine.

[3]  T. F. Rinke de Wit,et al.  Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children , 2017, The Journal of antimicrobial chemotherapy.

[4]  M. Cotton,et al.  Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis , 2017, Expert opinion on pharmacotherapy.

[5]  J. Homberg,et al.  Rethinking the risk-benefit ratio of efavirenz in HIV-infected children. , 2016, The Lancet. Infectious diseases.

[6]  T. F. Rinke de Wit,et al.  High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children , 2016, Journal of the International AIDS Society.

[7]  T. F. Rinke de Wit,et al.  Sequencing paediatric antiretroviral therapy in the context of a public health approach , 2015, Journal of the International AIDS Society.

[8]  W. Tsai,et al.  Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial. , 2015, JAMA.

[9]  E. Acosta,et al.  Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093 , 2015, The Pediatric infectious disease journal.

[10]  R. Viani,et al.  Use of Integrase Inhibitors in HIV-Infected Children and Adolescents , 2015, Drugs.

[11]  N. Ford,et al.  Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials , 2015, Journal of acquired immune deficiency syndromes.

[12]  J. H. van de Wijgert,et al.  Safety and Effectiveness of Combination Antiretroviral Therapy during the First Year of Treatment in HIV-1 Infected Rwandan Children: A Prospective Study , 2014, PloS one.

[13]  L. Morris,et al.  Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis , 2014, AIDS.

[14]  E. Lowenthal,et al.  Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz , 2014, Pediatric health, medicine and therapeutics.

[15]  Kara Wools-Kaloustian,et al.  Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. , 2012, International journal of epidemiology.

[16]  M. Hughes,et al.  Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. , 2012, The New England journal of medicine.

[17]  M. Egger,et al.  Virologic Failure and Second-Line Antiretroviral Therapy in Children in South Africa—The IeDEA Southern Africa Collaboration , 2011, Journal of acquired immune deficiency syndromes.

[18]  M. Hughes,et al.  Antiretroviral treatment for children with peripartum nevirapine exposure. , 2010, The New England journal of medicine.

[19]  T. Puthanakit,et al.  Predictors of Virologic Failure and Genotypic Resistance Mutation Patterns in Thai Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral Therapy , 2009, The Pediatric infectious disease journal.